within Pharmacolibrary.Drugs.ATC.L;

model L04AC03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.042666666666666665,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.00813,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Anakinra is a recombinant, non-glycosylated human interleukin-1 receptor antagonist (IL-1Ra) protein used for the treatment of rheumatoid arthritis and other autoinflammatory conditions. Anakinra blocks the biological activity of interleukin-1 by competitively inhibiting its binding to the interleukin-1 type I receptor (IL-1RI), and is approved for use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (median age 32 years, range 20–44), single subcutaneous (s.c.) injection.</p><h4>References</h4><ol><li><p>Mehta, P, et al., &amp; Tattersall, RS (2020). Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. <i>The Lancet. Rheumatology</i> 2(6) e358–e367. DOI:<a href=&quot;https://doi.org/10.1016/S2665-9913(20)30096-5&quot;>10.1016/S2665-9913(20)30096-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32373790/&quot;>https://pubmed.ncbi.nlm.nih.gov/32373790</a></p></li><li><p>Cvetkovic, RS, &amp; Keating, G (2002). Anakinra. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 16(4) 303–314. DOI:<a href=&quot;https://doi.org/10.2165/00063030-200216040-00005&quot;>10.2165/00063030-200216040-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12196041/&quot;>https://pubmed.ncbi.nlm.nih.gov/12196041</a></p></li><li><p>Nguyen, T, et al., &amp; Willett, KC (2023). Anakinra-An Interleukin-1 Receptor Antagonist for COVID-19. <i>American journal of therapeutics</i> 30(2) e108–e116. DOI:<a href=&quot;https://doi.org/10.1097/MJT.0000000000001603&quot;>10.1097/MJT.0000000000001603</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36811898/&quot;>https://pubmed.ncbi.nlm.nih.gov/36811898</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC03;
